URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Alan Katz

Concepts (149)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of pubs Most recent pub Pubs by all authors Concept score Why?
Radiosurgery
9
2006
74
2.040
Why?
Liver Neoplasms
7
2006
152
1.790
Why?
Neoplasm Metastasis
5
2006
229
1.060
Why?
Carcinoma, Hepatocellular
2
2011
68
0.990
Why?
Liver Transplantation
1
2011
238
0.670
Why?
Dose Fractionation
6
2006
58
0.500
Why?
Tumor Burden
4
2006
23
0.470
Why?
Neoplasms, Second Primary
3
1996
124
0.460
Why?
Lung Neoplasms
6
2000
428
0.460
Why?
Retrospective Studies
11
1997
2260
0.440
Why?
Breast Neoplasms
4
2000
675
0.440
Why?
Aged
22
1996
7272
0.430
Why?
Radiotherapy
2
2000
198
0.410
Why?
Aged, 80 and over
15
1997
2513
0.400
Why?
Vagina
1
2001
51
0.390
Why?
Endometrial Neoplasms
1
2001
37
0.390
Why?
Middle Aged
21
1996
9877
0.380
Why?
Brachytherapy
4
2000
111
0.380
Why?
Uterine Cervical Neoplasms
1
2001
124
0.370
Why?
Neoplasms, Radiation-Induced
1
2000
78
0.350
Why?
Carcinoma, Merkel Cell
4
1996
11
0.340
Why?
Skin Neoplasms
5
1996
231
0.340
Why?
Hodgkin Disease
1
2000
153
0.320
Why?
Female
23
1996
19826
0.310
Why?
Neoplasm Recurrence, Local
4
2000
286
0.300
Why?
Antineoplastic Combined Chemotherapy Protocols
4
1997
430
0.290
Why?
Adult
20
1996
11345
0.290
Why?
Humans
29
1996
36400
0.280
Why?
Stereotaxic Techniques
2
2006
33
0.280
Why?
Treatment Outcome
9
1997
2623
0.280
Why?
Brain Neoplasms
3
2006
282
0.280
Why?
Whole-Body Irradiation
2
2006
82
0.270
Why?
Male
19
1996
19713
0.240
Why?
Waiting Lists
1
2011
12
0.210
Why?
Cholangiocarcinoma
1
2012
13
0.210
Why?
Airway Obstruction
2
2000
37
0.200
Why?
Necrosis
1
2011
105
0.200
Why?
Bone Neoplasms
3
2006
206
0.200
Why?
Organ Size
1
2011
194
0.200
Why?
Radiotherapy Dosage
6
2000
203
0.200
Why?
Neoplasm Staging
3
2001
335
0.180
Why?
Remission Induction
2
2003
163
0.170
Why?
Sarcoma, Kaposi
2
1998
15
0.170
Why?
Thoracic Neoplasms
1
2009
19
0.170
Why?
Feasibility Studies
2
2006
205
0.170
Why?
Rectal Neoplasms
1
2010
83
0.170
Why?
Adrenal Gland Neoplasms
1
2009
36
0.170
Why?
Gene Expression Regulation, Neoplastic
1
2011
254
0.170
Why?
Neoplasms
2
1999
723
0.170
Why?
Carcinoma, Squamous Cell
2
2006
232
0.160
Why?
Radiation Injuries
2
2006
130
0.160
Why?
Survival Rate
4
2009
619
0.160
Why?
Cognition Disorders
1
2011
278
0.150
Why?
Liver
1
2011
876
0.150
Why?
Glioma
1
2008
102
0.150
Why?
Adenocarcinoma
2
2006
423
0.150
Why?
Prospective Studies
4
2008
1677
0.130
Why?
Follow-Up Studies
4
2003
1857
0.120
Why?
Tumor Markers, Biological
1
2006
228
0.120
Why?
Survival Analysis
5
1996
598
0.110
Why?
Pilot Projects
3
2008
441
0.110
Why?
Lymphatic Metastasis
4
1997
136
0.110
Why?
Etoposide
2
1997
83
0.110
Why?
Fluorouracil
2
1997
76
0.110
Why?
Bronchial Diseases
1
2001
8
0.100
Why?
Radiodermatitis
1
2001
8
0.100
Why?
Lung Diseases, Obstructive
1
2001
41
0.100
Why?
Constriction, Pathologic
1
2001
72
0.100
Why?
Dermatologic Agents
1
2001
24
0.100
Why?
Sesquiterpenes
1
2001
25
0.100
Why?
Medical Records
1
2001
125
0.100
Why?
Umbilicus
1
2000
4
0.090
Why?
Cholecystectomy
1
2000
16
0.090
Why?
Abdominal Neoplasms
1
2000
17
0.090
Why?
Gallbladder Neoplasms
1
2000
8
0.090
Why?
Fatty Acids
1
2001
98
0.090
Why?
Palliative Care
2
1999
159
0.090
Why?
Lipids
1
2001
167
0.090
Why?
Nucleic Acid Synthesis Inhibitors
1
2000
11
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2001
94
0.090
Why?
Antimetabolites, Antineoplastic
1
1999
38
0.090
Why?
Prognosis
3
1997
1080
0.090
Why?
Carcinoma
1
2000
191
0.080
Why?
Double-Blind Method
2
2010
998
0.080
Why?
Laparoscopy
1
2000
189
0.080
Why?
Melanoma
1
1999
135
0.080
Why?
Dose-Response Relationship, Radiation
2
2006
218
0.070
Why?
Treatment Failure
2
2006
130
0.070
Why?
Multivariate Analysis
3
1997
531
0.070
Why?
Israel
3
1996
39
0.060
Why?
Cisplatin
3
1997
94
0.060
Why?
Analysis of Variance
2
1997
725
0.060
Why?
Tomography, X-Ray Computed
2
2006
765
0.060
Why?
Sarcoma
1
2011
63
0.050
Why?
Esophageal Neoplasms
1
2011
57
0.050
Why?
Head and Neck Neoplasms
1
2011
84
0.050
Why?
Interleukin-8
1
2011
111
0.050
Why?
Medical Illustration
1
2010
10
0.050
Why?
Radiation Oncology
1
2010
18
0.050
Why?
Radiotherapy, Conformal
1
2010
19
0.050
Why?
Chemokine CCL2
1
2011
128
0.050
Why?
Colorectal Neoplasms
1
2011
136
0.050
Why?
Observer Variation
1
2010
143
0.040
Why?
Time Factors
2
1999
3201
0.040
Why?
Gastrointestinal Tract
1
2009
24
0.040
Why?
Interleukin-6
1
2011
340
0.040
Why?
Cohort Studies
1
2012
969
0.040
Why?
Jews
2
1996
9
0.040
Why?
Combined Modality Therapy
2
1997
486
0.040
Why?
Comorbidity
1
2009
374
0.040
Why?
Kaplan-Meier Estimate
1
2008
224
0.040
Why?
Young Adult
1
2012
1074
0.040
Why?
Disease Progression
1
2009
519
0.040
Why?
Radiotherapy, Computer-Assisted
1
2006
15
0.030
Why?
Antineoplastic Protocols
1
2006
3
0.030
Why?
Kidney
1
2009
582
0.030
Why?
Emulsions
1
2001
10
0.020
Why?
Skin Pigmentation
1
2001
13
0.020
Why?
Mastectomy, Segmental
1
2001
25
0.020
Why?
Administration, Topical
1
2001
89
0.020
Why?
Antineoplastic Agents, Hormonal
1
2001
46
0.020
Why?
Tamoxifen
1
2001
84
0.020
Why?
Iridium Radioisotopes
1
2000
15
0.020
Why?
Fiber Optic Technology
1
2000
25
0.020
Why?
Postoperative Period
1
2000
85
0.020
Why?
Bronchoscopy
1
2000
29
0.020
Why?
Mitomycin
1
1999
18
0.020
Why?
Bleomycin
1
1999
46
0.020
Why?
Carboplatin
1
1999
30
0.020
Why?
Ethnic Groups
1
2001
146
0.020
Why?
Infusions, Intravenous
1
1999
139
0.020
Why?
Administration, Oral
1
2000
309
0.020
Why?
Arabs
1
1998
2
0.020
Why?
Radiotherapy, Adjuvant
1
1999
73
0.020
Why?
Incidence
1
2001
679
0.020
Why?
Immunocompromised Host
1
1998
82
0.020
Why?
Radiotherapy, High-Energy
1
1997
24
0.020
Why?
Vincristine
1
1997
61
0.020
Why?
Neoplasms, Multiple Primary
1
1997
43
0.020
Why?
Methotrexate
1
1997
71
0.020
Why?
Cyclophosphamide
1
1997
173
0.020
Why?
Doxorubicin
1
1997
109
0.020
Why?
Sunlight
1
1996
15
0.020
Why?
Practice Guidelines as Topic
1
1999
304
0.020
Why?
Sex Distribution
1
1996
154
0.020
Why?
Dose-Response Relationship, Drug
1
1999
1138
0.020
Why?
Age Distribution
1
1996
216
0.020
Why?
Registries
1
1996
223
0.020
Why?
Adolescent
1
1999
4752
0.010
Why?

Visualizations


Katz's Networks

Concepts
_
Co-Authors
_
Same Department